Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESBA1008 vs Lucentis in Exudative AMD
NCT01304693Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Oct 2010
- Primary completion
- Mar 2013
- Modality
- scFv Fragments, Monoclonal Antibodies
01
Overview
A Phase 2 trial of brolucizumab in exudative age-related macular degeneration, sponsored by Alcon Inc.. Started Oct 2010; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01304693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01304693.